Menopause HRT and hair loss are closely linked concerns for many women navigating perimenopause and beyond. Declining oestrogen levels can disrupt the hair growth cycle, leading to increased shedding and reduced density, while the relative rise in androgens may trigger female pattern hair loss. Hormone replacement therapy (HRT) may help by restoring oestrogen and supporting the hair follicle environment, but it is not a licensed hair loss treatment. This article explains why menopause causes hair thinning, how HRT may help, which formulations matter, and what other evidence-based options are available alongside it.
Summary: Menopause can cause hair thinning due to falling oestrogen levels, and HRT may help by supporting the hair growth cycle, though it is not a licensed treatment for hair loss.
- Declining oestrogen during menopause shortens the hair growth (anagen) phase, increasing shedding and reducing density.
- A relative rise in androgens such as DHT can trigger female pattern hair loss (FPHL), presenting as diffuse thinning across the crown.
- HRT is not licensed for hair loss; NICE NG23 recommends it primarily for vasomotor symptoms such as hot flushes and night sweats.
- Progestogens with lower androgenic activity — such as micronised progesterone — are often preferred when hair loss is a concern.
- Topical minoxidil is the only UK-licensed treatment for female pattern hair loss and requires consistent long-term use.
- Scarring alopecias such as frontal fibrosing alopecia require prompt dermatology referral, as permanent follicle loss can occur if untreated.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Why Menopause Can Cause Hair Loss
Falling oestrogen during menopause shortens the hair growth phase and increases shedding, while a relative rise in androgens can cause female pattern hair loss. Thyroid disease, nutritional deficiencies, and stress can compound the problem.
Not sure if this is normal? Chat with one of our pharmacists →
Hair loss during menopause is more common than many people realise, yet it remains an underacknowledged symptom. The primary driver is the significant decline in oestrogen levels that occurs during the perimenopause and menopause. Oestrogen plays an important role in prolonging the anagen (growth) phase of the hair cycle. As levels fall, hair follicles may spend more time in the telogen (resting) phase, leading to increased shedding and reduced hair density. Progesterone is also thought to influence the hair cycle, though the evidence for its direct effect on hair follicles is less established than for oestrogen.
At the same time, the relative increase in androgens — such as testosterone and dihydrotestosterone (DHT) — that occurs as oestrogen declines can contribute to a pattern of hair thinning known as female pattern hair loss (FPHL). This typically presents as diffuse thinning across the crown and top of the scalp, rather than the receding hairline more commonly seen in men.
Other factors associated with menopause can compound hair loss, including:
-
Chronic stress and poor sleep, both of which can trigger telogen effluvium (a temporary but significant increase in hair shedding)
-
Nutritional deficiencies, particularly low ferritin (iron stores); associations with vitamin D and zinc have been reported, though these are largely observational and testing before supplementation is advisable
-
Thyroid disease, which is common in midlife and independently causes hair thinning — it should be considered as part of any assessment
It is important to be aware that some women in the postmenopausal years may develop scarring alopecias, such as frontal fibrosing alopecia (FFA) or lichen planopilaris. These are distinct conditions that require prompt specialist assessment. Red flags include scalp pain, burning or tenderness, perifollicular scaling, and progressive recession of the frontal hairline or loss of eyebrows. If any of these features are present, early referral to a consultant dermatologist is recommended, as scarring alopecias can cause permanent follicle loss if untreated.
Not all menopausal women will experience noticeable hair loss, and the severity varies considerably between individuals. A thorough assessment is needed to identify whether hormonal changes, nutritional factors, an underlying medical condition, or a combination of causes is responsible.
| Treatment / Approach | Type | Evidence for Hair Benefit | Key Considerations | UK Regulatory Status |
|---|---|---|---|---|
| Oestrogen (transdermal: patch, gel, spray) | HRT component | Observational; may re-extend anagen phase and reduce androgenic environment | Transdermal route associated with lower VTE risk than oral (NICE NG23) | Licensed for menopausal symptoms; not licensed for hair loss |
| Micronised progesterone (e.g. Utrogestan) | HRT progestogen | Limited; minimal androgenic activity, preferred by BMS when hair loss is a concern | BMS favours this over synthetic progestogens; NICE NG23 does not specifically recommend it as safer | Licensed for endometrial protection in HRT; not licensed for hair loss |
| Norethisterone / levonorgestrel | HRT progestogen | May worsen hair thinning in susceptible individuals due to higher androgenic activity | Consider switching progestogen if hair loss worsens after starting HRT | Licensed HRT progestogens; not recommended first choice where hair loss is a concern |
| Topical minoxidil (2% or 5%) | Licensed hair treatment | Best-evidenced option for FPHL; prolongs anagen phase, enlarges miniaturised follicles | Requires ≥6 months consistent use; hair loss returns on stopping; avoid in pregnancy | Only UK-licensed treatment for female pattern hair loss (FPHL); OTC available |
| Spironolactone / finasteride / dutasteride | Anti-androgen (specialist) | Used off-label for FPHL, particularly postmenopausal women; specialist supervision required | Contraindicated in women who may become pregnant; requires monitoring by consultant dermatologist | Off-label use in UK; initiated by specialist only |
| Ferritin / vitamin D optimisation | Nutritional | Observational associations with hair loss; supplementation unproven unless deficiency confirmed | Test before supplementing; NHS recommends 10 mcg (400 IU) vitamin D daily in autumn/winter | No licensed indication for hair loss; guided by blood test results |
| Biotin (vitamin B7) | Nutritional supplement | Deficiency rare; no proven benefit for hair unless deficient | High-dose biotin interferes with thyroid and troponin blood tests; inform GP before testing (MHRA Drug Safety Update) | Not licensed for hair loss; use with caution |
How HRT May Help With Menopausal Hair Thinning
HRT may help by restoring oestrogen levels, potentially re-extending the hair growth cycle and reducing the androgenic environment that drives follicular miniaturisation. It is not a licensed hair loss treatment, and any hair benefit is a secondary gain.
Hormone replacement therapy (HRT) works by replenishing the oestrogen (and, where appropriate, a progestogen) that declines during menopause. By restoring oestrogen levels, HRT may help to re-extend the hair growth cycle, potentially reducing excessive shedding and supporting the maintenance of hair density over time. Some women report an improvement in hair thickness and quality after starting HRT, though individual responses vary considerably and the evidence for this benefit is largely observational.
Oestrogen is thought to act on hair follicles both directly — by binding to oestrogen receptors within the follicle — and indirectly, by reducing the relative androgenic environment that promotes follicular miniaturisation. These mechanisms are plausible but should be understood as hypotheses rather than established fact, as robust clinical trial data specifically on hair outcomes are limited.
It is important to set realistic expectations. HRT is not a licensed treatment for hair loss. NICE guidance (NG23) recommends HRT primarily for the management of vasomotor symptoms (such as hot flushes and night sweats) and may be considered for low mood related to menopause; it is not recommended as a treatment for clinical depression. Any benefit to hair should be considered a potential secondary gain rather than a primary indication for HRT.
Women who start HRT for other menopausal symptoms may notice gradual improvements in hair quality over several months. Conversely, some women find that certain progestogens — particularly those with higher androgenic activity — may not improve, and could potentially worsen, hair thinning, though direct evidence for this in clinical practice is limited. This makes the choice of HRT formulation relevant when hair loss is a concern.
If you experience any suspected side effects from HRT or other medicines, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
Experiencing these side effects? Our pharmacists can help you navigate them →
Types of HRT and Their Effects on Hair
Progestogens with higher androgenic activity, such as norethisterone, may worsen hair thinning in susceptible women, while micronised progesterone is often preferred due to its minimal androgenic activity. Transdermal oestrogen is associated with lower VTE risk compared with oral oestrogen.
Not all HRT formulations are equal when it comes to their potential impact on hair. The oestrogen component of HRT is generally considered beneficial for hair, but the progestogen component — required in women with an intact uterus to protect the womb lining — can vary in its androgenic activity, and this may be relevant for some women.
Progestogens and androgenic activity:
-
Norethisterone and levonorgestrel are older synthetic progestogens with relatively higher androgenic activity. They may bind to androgen receptors in hair follicles and could potentially contribute to hair thinning in susceptible individuals, though direct clinical evidence for this effect on hair is limited.
-
Dydrogesterone has lower androgenic activity and is generally considered more hair-neutral, though again robust comparative hair data are lacking.
-
Medroxyprogesterone acetate has a complex pharmacological profile; it is sometimes described as having lower androgenic activity, but evidence specifically relating to hair outcomes is limited.
-
Micronised progesterone is a body-identical progestogen with minimal androgenic activity. The British Menopause Society (BMS) indicates it may have a more favourable risk profile compared with some synthetic progestogens, based on observational data, and it is often preferred when hair loss is a concern. It is important to note that NICE NG23 does not specifically recommend micronised progesterone as a 'safer' option over other progestogens; the BMS position reflects evolving evidence rather than established guideline consensus.
Oestrogen delivery routes are also relevant. Transdermal oestrogen (patches, gels, or sprays) is associated with a lower risk of venous thromboembolism (VTE) compared with oral oestrogen, as noted in NICE NG23. Some specialists favour transdermal routes for women with hair concerns, as they avoid first-pass liver metabolism and may provide more stable oestrogen levels; however, direct evidence that this translates into better hair outcomes is limited.
For women who have had a hysterectomy and take oestrogen-only HRT, the absence of a progestogen removes this variable entirely. In all cases, the choice of HRT should be made collaboratively with a GP or menopause specialist, taking into account the full clinical picture, personal preferences, and individual risk factors.
Other Treatment Options Alongside HRT
Topical minoxidil is the only UK-licensed treatment for female pattern hair loss and can be used alongside HRT. Nutritional deficiencies, particularly low ferritin, should be identified by blood tests and treated before supplementation is started.
HRT alone may not fully address menopausal hair loss, and a multimodal approach is often most effective. Several evidence-based and supportive treatments can be used alongside HRT to optimise hair health.
Topical minoxidil is the only treatment currently licensed in the UK for female pattern hair loss (FPHL). Available over the counter as a 2% or 5% solution or foam, its precise mechanism is not fully understood but is thought to involve prolonging the anagen phase and enlarging miniaturised follicles. It requires consistent, long-term use — typically at least six months before meaningful results are seen — and hair loss is likely to return if treatment is stopped. Common local side effects include scalp irritation and, less commonly, unwanted facial hair growth. Minoxidil should not be used during pregnancy or breastfeeding. Women should discuss suitability with a pharmacist or GP before starting.
Nutritional optimisation is an important and often overlooked component. Blood tests to identify deficiencies should guide supplementation rather than routine supplementation without testing:
-
Ferritin (iron stores): Confirmed iron deficiency should be investigated and treated. Some experts suggest that ferritin levels in the lower part of the normal range may be suboptimal for hair follicle function, though there is no universally agreed UK threshold for hair loss specifically; any supplementation should be guided by a clinician.
-
Vitamin D: Deficiency is common in the UK. NHS guidance recommends that adults consider taking 10 micrograms (400 IU) of vitamin D daily, particularly in autumn and winter. Whilst vitamin D deficiency has been associated with hair loss in observational studies, supplementation has not been proven to improve hair growth in the absence of deficiency.
-
Biotin (vitamin B7): Biotin deficiency is rare. If supplementation is being considered, it is important to be aware that high-dose biotin can interfere with a range of laboratory blood tests, including thyroid function tests and troponin assays, potentially producing misleading results. The MHRA has issued a Drug Safety Update on this risk; inform your GP or any healthcare professional if you are taking biotin supplements before having blood tests.
-
Zinc and protein intake support overall hair structure, but supplementation should only be considered where deficiency is confirmed.
Anti-androgen treatments may be considered for some women with FPHL, particularly postmenopausal women, under specialist supervision. Options used off-label in the UK include spironolactone and, in postmenopausal women, finasteride or dutasteride. These are not suitable for women who may become pregnant due to the risk of harm to a male foetus, and they require careful monitoring. They would typically be initiated and overseen by a consultant dermatologist or specialist.
Scalp care and low-level laser therapy (LLLT) devices have some emerging evidence for stimulating follicular activity, but the evidence base is mixed and these are not routinely commissioned by the NHS. Referral to a consultant dermatologist is recommended for persistent, complex, or uncertain hair loss, particularly where a scarring alopecia is suspected. Trichologists — specialists in hair and scalp health — are not medically regulated in the UK, but reputable practitioners may be found through the Institute of Trichologists or the Trichological Society. They can provide a detailed assessment and supportive advice, but medical diagnosis and prescribing remain within the remit of registered clinicians. Psychological support may also be beneficial, as hair loss can significantly affect self-esteem and quality of life.
When to Speak to a GP or Specialist
You should see a GP if you notice sudden shedding, patchy loss, scalp pain or burning, or hair loss accompanied by systemic symptoms such as fatigue or weight changes. Prompt dermatology referral is essential if a scarring alopecia such as frontal fibrosing alopecia is suspected.
Many women feel embarrassed or uncertain about raising hair loss with their GP, but it is a legitimate medical concern that warrants proper assessment. You should make an appointment if you notice:
-
Sudden or rapid hair shedding, particularly if large amounts are coming out when washing or brushing
-
Patchy hair loss or bald spots, which may suggest alopecia areata — an autoimmune condition unrelated to menopause
-
Scalp pain, burning, tenderness, perifollicular scaling, or progressive recession of the frontal hairline or eyebrows, which may indicate a scarring alopecia such as frontal fibrosing alopecia (FFA) — prompt dermatology referral is important in these cases
-
Hair loss accompanied by other symptoms such as fatigue, weight changes, cold intolerance, or skin changes, which could indicate thyroid dysfunction or another systemic condition
-
Scalp symptoms such as itching, scaling, or inflammation, which may point to a dermatological cause requiring specialist input
-
Significant psychological distress related to hair changes
As part of your assessment, it is also worth reviewing any medicines you are currently taking — a number of commonly used drugs, including some antidepressants, antihypertensives, and anticoagulants, can contribute to hair loss. Hair-care practices such as tight hairstyles or extensions (traction alopecia) should also be considered.
A GP will typically begin with a focused history and blood tests. Investigations usually include full blood count (FBC), ferritin, and thyroid-stimulating hormone (TSH). Vitamin B12 and vitamin D may also be checked. Androgen levels are not routinely tested for hair loss unless there are clinical features suggesting hyperandrogenism or polycystic ovary syndrome (PCOS), such as irregular periods, acne, or hirsutism. Routine sex hormone testing (such as FSH) is not generally needed to diagnose menopause in women over 45 with typical symptoms. If an underlying cause is identified, treating it directly is the priority.
If hair loss is persistent, complex, or the diagnosis is uncertain, referral to a consultant dermatologist is appropriate. The British Association of Dermatologists (BAD) provides a 'find a dermatologist' directory. If a scarring alopecia is suspected, this referral should be made promptly. Some women also choose to access private menopause or trichology clinics for additional support; the British Menopause Society (BMS) provides a directory of accredited menopause specialists.
Early intervention tends to yield better outcomes. Hair follicles that have been dormant for a prolonged period are less likely to recover fully, so seeking advice promptly — rather than waiting to see if the problem resolves on its own — is generally advisable.
Frequently Asked Questions
How long does it take for HRT to improve hair loss during menopause?
Most women who notice hair improvements on HRT report gradual changes over several months, typically three to six months or longer, as the hair growth cycle is slow to respond. Individual results vary considerably, and HRT is not a licensed treatment for hair loss, so improvement cannot be guaranteed.
Can HRT make menopausal hair loss worse?
Some progestogens with higher androgenic activity — such as norethisterone or levonorgestrel — may potentially worsen hair thinning in susceptible women, though direct clinical evidence is limited. If hair loss is a concern, discussing a formulation with lower androgenic activity, such as micronised progesterone, with your GP or menopause specialist is advisable.
Is minoxidil safe to use at the same time as HRT?
Topical minoxidil and HRT are generally used together without known interactions, as minoxidil acts locally on the scalp rather than systemically. You should discuss your full medication list with a pharmacist or GP before starting minoxidil to confirm it is suitable for you.
What is the difference between menopausal hair loss and alopecia areata?
Menopausal hair loss typically presents as diffuse thinning across the crown and top of the scalp, driven by hormonal changes, whereas alopecia areata causes distinct patchy bald spots and is an autoimmune condition unrelated to menopause. If you notice patchy loss or bald spots, you should see a GP for a proper assessment rather than assuming it is hormone-related.
Do I need a blood test before starting treatment for menopause-related hair loss?
Yes — a GP will usually check a full blood count, ferritin, and thyroid-stimulating hormone (TSH) to rule out treatable causes such as iron deficiency or thyroid disease before attributing hair loss to menopause. Vitamin D and B12 may also be checked, and any deficiencies identified should be treated before considering supplementation.
Can I get treatment for menopausal hair loss on the NHS?
A GP can assess, investigate, and prescribe HRT or refer you to a consultant dermatologist on the NHS if hair loss is persistent or complex. Topical minoxidil is available over the counter without a prescription, but some specialist treatments such as anti-androgens would require a specialist referral and are prescribed off-label.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
